Equillium is a clinical-stage biotechnology company. Co. develops products for severe autoimmune and inflammatory, or immuno-inflammatory, disorders with unmet medical need. Co.'s initial product candidate, itolizumab (EQ001), is a clinical-stage, monoclonal antibody that selectively targets the immune checkpoint receptor CD6. CD6 plays a central role in the modulation of effector T cell (Teff cell) activity and trafficking. Activated Teff cells drive a number of immuno-inflammatory diseases across therapeutic areas including transplant science, systemic autoimmunity, pulmonary, neurologic, gastrointestinal, renal, vascular, ophthalmic and dermatologic disorders. The EQ stock yearly return is shown above.
The yearly return on the EQ stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2020 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the EQ annual return calculation with any dividends reinvested as applicable (on ex-dates).
|